Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489809 | 0.83 | — | — | |
| SCHEMBL14659291 | 0.79 | SIGMAR1 (0.35) | CYP1A2SIGMAR1EPHX1 | |
| SCHEMBL23014799 | 0.74 | CYP1A2 (0.39) | CYP1A2SIGMAR1HTTMEN1KMT2A | |
| SCHEMBL18902841 | 0.74 | CYP1A2 (0.39) | CYP1A2SIGMAR1HTTMEN1KMT2A | |
| SCHEMBL983446 | 0.73 | THRB (0.42) | HTTMEN1KMT2A | |
| SCHEMBL982845 | 0.73 | THRB (0.42) | HTTMEN1KMT2A | |
| SCHEMBL984576 | 0.73 | THRB (0.42) | HTTMEN1KMT2A | |
| SCHEMBL134426 | 0.73 | THRB (0.42) | HTTMEN1KMT2A | |
| SCHEMBL133829 | 0.73 | THRB (0.42) | HTTMEN1KMT2A | |
| SCHEMBL982532 | 0.73 | THRB (0.42) | HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-06 | — | — | US | claimed |
| US-9475832-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-25 | — | — | US | claimed |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION | 2015-03-19 | — | — | US | claimed |
| US-8846643-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-30 | — | — | US | claimed |
| EP-2558466-A2 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | The Regents of the University of California (US) | 2013-02-20 | — | — | EP | claimed |
| US-20130029940-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-31 | — | — | US | claimed |
| WO-2011130557-A2 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-20 | — | — | WO | claimed |
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-06 | — | — | US | disclosed |
| US-9475832-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-8846643-B2 | Phosphonates with reduced toxicity for treatment of viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2558466-A2 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | The Regents of the University of California (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130029940-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2011130557-A2 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096441-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | CYP1A2 3184/4885SIGMAR1 2068/4885HTT 1612/4885 |
| US-20130029940-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | CYP1A2 3184/4885SIGMAR1 2068/4885HTT 1612/4885 |
| US-20150080344-A1 | PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS | POLRMT, PNP, MTAP | CYP1A2 3184/4885SIGMAR1 2068/4885HTT 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.